Apogee Therapeutics

Historical price data

Apogee Therapeutics is a clinical-stage biotech with a mission to reshape the standard of care in inflammatory and immune (I&I) diseases by developing superior, half-life extended antibody therapies. Its lead asset, zumilokibart (APG777), an anti-IL-13, has shown positive Phase 2 data in atopic dermatitis and is advancing in asthma and eosinophilic esophagitis. The company's strategy leverages a proprietary FcRn engineering platform to create less frequent dosing regimens and is pursuing both monotherapy and novel combination approaches to capture significant share in large, validated markets.

Proprietary antibody engineering platform focused on optimizing binding to the neonatal Fc receptor (FcRn) to significantly extend serum half-life, enabling less frequent dosing (e.g., every 3-6 months) compared to standard monoclonal antibodies.